Answers are grounded in this paper and cite their sources.
Retrospective analysis of treatment outcomes for RPLN metastases in thyroid cancer patients, highlighting surgical options and non-invasive approaches.
Background Retropharyngeal lymph node (RPLN) metastases in thyroid cancer are rare, with optimal management underreported. Methods Retrospective study of consecutive thyroid cancer patients with RPLN metastases treated at MD Anderson Cancer Center between 2000 and 2024. Results One hundred and sixty‐seven patients (75% differentiated, 21% medullary, 4% poorly differentiated thyroid cancer) were divided into three groups: active surveillance (AS) (13%), surgery (56%), and nonsurgical treatment (31%). In the AS group (median follow‐up 2.3 years), RPLN metastases grew a median 3% (range: 0–56) or 0.02 cm (range: 0–0.7) per year. Surgical therapy included transcervical (73%), transoral robotic (14%), transoral (12%), and transmandibular (1%) approaches. Median RPLN metastasis size was 1.7 cm (interquartile range: 1.3–2.2) at surgery. Three months post‐operatively, 11% had dysphagia and 1% had velopharyngeal insufficiency. Nonsurgical treatments included radioactive iodine (10%), radiation therapy (11%), and systemic targeted therapy (79%). Conclusion RPLN metastases grow slowly, and those ≥ 1 cm typically undergo surgical resection without significant long‐term morbidity.
No takes yet. Share an insight, caveat, or question.
Fournier et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: